Table 3.

CMH trend test on cetuximab response by frequencies of MUT APC (A) and/or MUT TP53 (P) in cetuximab-treated colorectal cancer PDX models

Julien all PDX models (n = 52)Julien WT KRAS (n = 25)Bertotti PDX models (n = 98)*
ResponseMutationMutationMutation
Frequency expected cell χ2Col PCTAPA or PWT APTotalAPA or PWT APTotalAPA or PWT APTotal
CR/PR & SD10801875012616673
6·929·351·734·86·720·4854·388·949·68
1·370·191·731·000·440·480·810·971·40
50·0029·630·0070·0035·710·0083·5650·0046·15
PD101953439113126725
13·0817·653·275·27·280·5218·623·063·32
0·720·100·920·930·410·442·362·824·09
50·0070·37100·0030·0064·29100·0016·4450·0053·85
Total2027552101412573121398
CMHDF111
(nonzeroValue4.853·5611.23
corr.)P0.02770·05920.0008
  • NOTE: For illustration purposes, the antitumor activities “+++,” “++,” and “+”/“-” in Julien and colleagues' PDX models were reexpressed as “CR/PR,” “SD,” and “PD”, respectively, according to the pharmacologic annotation as described previously (23). See Supplementary Tables S7 and S8 for detailed data description of Julien and colleagues (23) and Bertotti and colleagues (24) CTX-colorectal cancer PDX models, respectively. The significant values and P values of the CMH test are highlighted in bold.

  • Abbreviations: A, APC mutation; AP, APC mutation + TP53 mutation; MUT, mutant; P, TP53 mutation; PD, progressed disease; WT AP, WT APC + WT TP53.